Assessing The Predictive Significance Of N-terminal Pro-b-type Natriuretic Peptide In Patients With Sarcopenia Undergoing Transcatheter Aortic Valve Replacement
Ian Persits,Saeid Mirzai,Maximilian Volk,Jerry Estep,Po-Hao Chen,Grant Reed,Wai Hong Tang
DOI: https://doi.org/10.1016/j.cardfail.2023.10.077
IF: 6.592
2024-01-01
Journal of Cardiac Failure
Abstract:Introduction Sarcopenia and elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels are independent risk factors for worse outcomes in patients with cardiovascular diseases; however, their concomitant prognostic impact has not been studied in transcatheter aortic valve replacement (TAVR) recipients. Hypothesis We hypothesized that sarcopenia and elevated NT-proBNP levels are associated with worse outcomes in patients undergoing TAVR. Methods We included 236 consecutive patients undergoing TAVR from January to December 2018 with chest computed tomography within three months before the procedure date. Automated multi-slice measurements of skeletal muscle volume were made using the Data Analysis Facilitation Suite (Voronoi Health Analytics, Vancouver, Canada) from T9 to T12 and adjusted for height squared to obtain skeletal muscle index (SMI). To compare survival, patients were grouped based on sarcopenia (lowest sex-stratified SMI tertile cutoffs of 283.8 cm3/m2 in males and 195.4 cm3/m2 in females) and pre-procedure NT-proBNP (highest median cutoff of 1134 pg/mL). Results A total of 80 (33.9%) patients were identified as sarcopenic; compared to non-sarcopenic patients, they were older (83±7 vs. 79±9, p<0.001) with a higher STS mortality score (5.7 [3.6-7.8] vs. 4.1 [3.1-6.4], p=0.014) and NT-proBNP (1460 [616-3098] vs. 876 [305-2583], p=0.012). NT-proBNP further stratified the cohort into non-sarcopenic with lower NT-proBNP (controls; 36.0%), sarcopenic with lower NT-proBNP (14.0%), non-sarcopenic with higher NT-proBNP (30.1%), and sarcopenic with higher NT-proBNP (19.9%). Compared to controls, one-year readmission or mortality was highest among patients with sarcopenia with higher NT-proBNP (Figure 1A); this remained significant on adjustment for age, female sex, Caucasian race, STS mortality score, left ventricular ejection fraction, chronic kidney disease, chronic obstructive pulmonary disease, cirrhosis, and cancer (HR 4.67, 95%CI 2.17-10.06, p<0.001). Furthermore, over a median 43 (29-53) months of follow-up, patients with sarcopenia with higher NT-proBNP had higher all-cause mortality (Figure 1B), but all groups lost significance compared to controls after similar multivariable adjustment. Conclusions Among those undergoing TAVR, patients with sarcopenia and elevated NT-proBNP levels had the highest rates of one-year readmission or mortality despite multivariable adjustment for known predictors of poor outcome.
cardiac & cardiovascular systems